Last SSP was $19M and change.
The then CEO had this to say:
“This capital raising positions us strongly to fulfil our commercialisation objectives and fully funds our scheduled TPM®/opioid clinical trial programs. The capital raised is earmarked for our pivotal TPM®/Oxymorphone Phase 2 clinical trial in the USA scheduled for the first half of 2015 and our upcoming TPM®/Oxycodone Phase 2 trial in Australia,” said CEO, Harry Rosen.
“The capital raising comes at a time when the Company is focusing on exploiting the commercialisation of several of its lead programs. We have recently strengthened our business development capacity in the US to assist in this process. While we have unquestionably shown that our technology provides enhanced delivery solutions across a wide range of products, we now need to translate this to commercial outcomes,” said Harry Rosen.
What was commercialized?
Ann: Trading Halt, page-15
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.001(20.0%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $408 | 154.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 61 | 90794613 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 54998583 | 13 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |